A multi-billion dollar collaboration between Prime Medicine Inc. and Bristol-Myers Squibb brings this important technology closer to patients. At the end of 2023, the FDA already approved Casgevy (exagamglogene autotemcel), developed jointly by CRISPR Therapeutics and Vertex Pharmaceuticals for sickle cell disease and beta thalassemia, and bluebird bio’s Lyfgenia (lovotibeglogene autotemcel) for sickle cell disease. […]
Vicebio Announces $100 Million Series B Financing and Initiation of Phase 1 Clinical Study of RSV/hMPV Bivalent Vaccine Vicebio Ltd, a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, on Monday announced a $100 million Series B financing led by TCGX with investment from Goldman Sachs Alternatives, Avoro Ventures, venBio, and participation from UniQuest and founding investor Medicxi. London-based Vicebio said funding […]
MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus and Wacker Biotech, a contract development and manufacturing organisation, on Tuesday announced a collaboration to manufacture the active protein ingredients of MinervaX’s GBS vaccine. MinervaX will scale up supply of its novel GBS vaccine, ahead of commencing phase […]
Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for regenerating bone and managing infection in bone and soft tissue, on Thursday announced that it will begin distributing its NanoBone range of products in the UK. The range consists of NanoBone SBX Putty and NanoBone QD, which are next generation […]
AMSilk GmbH (“AMSilk”), a global leader in advanced biomaterials made from spider silk-based proteins, on Tuesday announced it has been invited to join the World Economic Forum’s Global Innovators Community. The Global Innovators Community, an invite-only initiative, was established in 2019 to bring together companies making strides to innovate and contribute meaningfully to solving the key […]
